Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model | Zendy

Razieh Kebriaei | Zendy; Seth Rice | Zendy; Kyle Stamper | Zendy; Michael J. Rybak | Zendy

Open Access

Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model

Author(s) -

Razieh Kebriaei,

Seth Rice,

Kyle Stamper,

Michael J. Rybak

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01743-18

Subject(s) - dalbavancin , pharmacokinetics , vancomycin , staphylococcus aureus , glycopeptide , pharmacodynamics , pharmacology , glycopeptide antibiotic , medicine , antibiotics , microbiology and biotechnology , biology , bacteria , genetics

Glycopeptides such as vancomycin have been used as the first-line therapy against MRSA infections for over half a century. Reduced susceptibility and emergence of resistance to first-generation glycopeptides has led to development of second-generation lipoglycopeptide derivatives such as dalbavancin which hold broader ranges of activity and enhanced pharmacokinetic properties.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research